Muscarinic Drugs: Research and Development Progress and Applications

Muscarinic acetylcholine receptors are G-protein-coupled receptors that regulate central and peripheral cholinergic signaling. For four decades, the M1 and M4 receptor programs have promised non-dopaminergic treatments for schizophrenia and cognitive disorders, but broad cholinergic activation repeatedly produced dose-limiting adverse effects. Interest returned with structure-based design, subtype-selective orthosteric agonists, positive allosteric modulators, and combinations that separate central efficacy from peripheral toxicity. The leading example pairs xanomeline, an M1/M4-preferring agonist, with trospium, a peripherally restricted muscarinic antagonist, creating a mechanistically distinct antipsychotic strategy that does not depend on dopamine D2 receptor blockade The renewed pipeline reflects a shift from asking whether muscarinic activation works to designing where, how strongly, and for how long it acts^[1][2].

The therapeutic logic is pharmacological separation. Xanomeline activates central muscarinic pathways associated with antipsychotic and procognitive effects, whereas trospium limits peripheral cholinergic events. Phase 2 and phase 3 trials in acute schizophrenia showed greater reductions in Positive and Negative Syndrome Scale scores than placebo, while adverse events remained predominantly gastrointestinal, autonomic, or cholinergic. Earlier development failed because target activation and tolerability could not be disentangled; current programs use receptor structure, selectivity, partial agonism, allostery, pharmacokinetics, and peripheral restriction to shape the exposure-response relationship. These principles apply broadly to difficult GPCR targets Peripheral restriction is especially important because efficacy and adverse effects arise from the same receptor family expressed in different tissues^[1][3][4].

Applications extend beyond acute psychosis. Muscarinic M1 activation is pursued for memory and cognitive impairment in Alzheimer disease, where existing cholinesterase inhibitors have limited efficacy. A structure-to-clinic program produced the selective partial M1 agonist HTL9936 and demonstrated activity in human memory centers after stepwise testing from atomic structure through preclinical and safety studies. Xanomeline's historical activity in schizophrenia and Alzheimer disease also stimulated safer subtype-focused ligands. In schizophrenia, muscarinic activators could address a pathway distinct from the common D2 mechanism, although durable effects on negative symptoms, cognition, relapse, and function require longer observation This program illustrates how medicinal chemistry, receptor pharmacology, and clinical trial design can jointly reopen a previously abandoned target class^[2][4][5][6].

Research gaps center on receptor subtype, circuit mechanism, and long-term safety. M1 and M4 can contribute differently across brain regions, while orthosteric agonists may lose selectivity at clinically relevant exposure. Trials must distinguish central target engagement from peripheral antagonism and determine whether symptom improvement persists beyond short inpatient studies. Comparative studies should assess metabolic, motor, cognitive, cardiovascular, and gastrointestinal outcomes against established antipsychotics. Biomarkers of receptor occupancy or downstream circuit response could improve dose selection and identify responsive patients. For Alzheimer disease, cognitive signals need confirmation in adequately powered trials. The next generation of muscarinic drugs will succeed only if molecular selectivity produces clinically meaningful selectivity rather than simply shifting adverse effects Post-approval and long-duration evidence will be needed to define uncommon adverse events, treatment adherence, and effectiveness in broader clinical populations. Comparative trials should also establish whether muscarinic efficacy extends to cognition and negative symptoms and whether peripheral blockade changes central exposure or response. Receptor-selective biomarkers could sharpen those comparisons^[1][5][6][7].